Guilherme Nader Marta· @GuiNaderMarta · X·· 1 天前评分70
正文 · 机器翻译
FourLight-1 由 @antgiorda 在 #ESMO26 报告
在接受 CDK4/6i 治疗后进展的 HR+/HER2− 转移性乳腺癌患者中，Atirmociclib + fulvestrant 相比研究者选择方案改善了中位PFS（9.4 vs 6.6个月；HR 0.60；p=0.0007）
@DFCI_BreastOnc @OncoAlert
104 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Guilherme Nader Marta · x.com